Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 8/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565048 | 0.86 | PPARA (0.44) | PPARGPPARAADRB3TP53MAPT | |
| SCHEMBL5569702 | 0.80 | FFAR4 (0.48) | FFAR4FFAR1PPARDPPARGPPARA | |
| SCHEMBL29061885 | 0.80 | FFAR4 (0.48) | FFAR4FFAR1PPARDPPARGPPARA | |
| SCHEMBL6390221 | 0.79 | PPARA (0.49) | FFAR4FFAR1PPARDPPARGPPARA | |
| SCHEMBL5565463 | 0.79 | VDR (0.49) | — | |
| SCHEMBL5646670 | 0.76 | PPARD (0.52) | FFAR4FFAR1PPARDPPARGPPARA | |
| SCHEMBL9319841 | 0.75 | PPARD (0.48) | PPARDPPARGPPARA | |
| SCHEMBL9319838 | 0.75 | PPARD (0.48) | PPARDPPARGPPARA | |
| SCHEMBL5650512 | 0.75 | PPARD (0.51) | FFAR4FFAR1PPARDPPARGPPARA | |
| SCHEMBL15801263 | 0.75 | BCHE (0.55) | FFAR1PPARDPPARGPPARAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312249-B2 | Vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-25 | — | — | US | disclosed |
| EP-1537065-B1 | ANALOGUES OF VITAMIN D | GALDERMA RES & DEV (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182144-A1 | Novel vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182144-A1 | Novel vitamin D analogues | CYP24A1, CYP2R1, VDR | FFAR4 347/4885FFAR1 290/4885PPARD 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.